Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 20, 2022
Data Byte

Colitis innovation in the Distillery spotlight

Targets include LRH-1, PYK2, BDNF, HSF1, ZDHHC7, LYPLA2 and cGas
BioCentury | Apr 1, 2022
Distillery Therapeutics

A synthetic LRH-1 agonist for ulcerative colitis

BioCentury | Feb 28, 2018
Distillery Therapeutics

Cancer

BioCentury | Jun 13, 2013
Distillery Therapeutics

Indication: Cancer

BioCentury | Oct 6, 2011
Distillery Therapeutics

Indication: Cancer

BioCentury | Jun 9, 2011
Distillery Therapeutics

Indication: Endocrine disease

BioCentury | Jun 9, 2011
Targets & Mechanisms

Nuclear receptor in the crosshairs of diabetes

Items per page:
1 - 7 of 7
Help Center
Username
Request a Demo
Request Training
Ask a Question